Glenmark Pharmaceuticals is currently trading at Rs. 794.70, up by 2.75 points or 0.35% from its previous closing of Rs. 791.95 on the BSE.
The scrip opened at Rs. 798.85 and has touched a high and low of Rs. 798.90 and Rs. 784.05 respectively. So far 9683 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 832.90 on 27-Jul-2023 and a 52 week low of Rs. 361.70 on 29-Aug-2022.
Last one week high and low of the scrip stood at Rs. 824.65 and Rs. 771.00 respectively. The current market cap of the company is Rs. 22220.74 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 34.67% and 18.69% respectively.
Glenmark Pharmaceuticals (Glenmark) has joined hands with OMRON Healthcare India, the Indian arm of the Japanese global leader in home blood pressure monitoring and solutions for cardiovascular disease management, to raise awareness on measuring blood pressure at home from the age of 18.
Glenmark and OMRON Healthcare India's collaboration, named as ‘Take Charge @18’ initiative, comprises of generating effective communication to enhance awareness around the cause via incorporating an inlay card into every OMRON Blood Pressure monitor sold in India. The message conveys the importance of initiating blood pressure screening at the right age which is 18 years.
The objective is to encourage patients and care givers who come across this inlay card to sensitize at least four family members of or above the age of 18 to start monitoring their blood pressure and make it a part of their health regime. This message will also be seamlessly integrated into the OMRON Connect app, ensuring it reaches all its subscribers and also on OMRON social media and websites.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1774.20 |
| Dr. Reddys Lab | 1205.00 |
| Cipla | 1479.85 |
| Lupin | 2057.45 |
| Zydus Lifesciences | 944.85 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
Become a savvy and confident
stock investor.
Don't miss out! First 10 users today get it FREE
Download APP
